Updated formulations target newer variants like JN.1, improving protection against circulating strains.
Effectiveness in 2025–2026
Hospitalization Protection:
Updated vaccines reduced hospitalizations by ~55% among adults with COV;;;-like illness.
Emergency Care Visits:
Effectiveness against ED/urgent care visits was ~50%, showing strong real-world impact.
Variant Adaptation: Omicron-adapted boosters provide superior protection compared to older monovalent doses.
Safety Profile
Adverse Events: Serious side effects remain rare, with most reactions mild (fever, fatigue, injection-site pain).
Long-term Data: Evidence shows sustained safety, though more research is needed for children, cancer patients, and immunocompromised groups.
WHO Guidance (2026)
Routine Vaccination:
Recommended for high-risk groups (elderly, immunocompromised, healthcare workers).
Coadministration:
